Citius Oncology, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CTOR Nasdaq 2834

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Citius Oncology, Inc.

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies - Jun 1st, 2026 5:00 am
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting - May 26th, 2026 6:00 am
Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts? - May 24th, 2026 5:49 am
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update - May 15th, 2026 2:30 pm
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update - May 15th, 2026 2:30 pm
Citius raises $36.5m for Lymphir commercialisation - May 6th, 2026 7:04 am
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization - May 5th, 2026 6:00 pm
Citius Oncology Ships First International Order of LYMPHIR™ to Europe - Apr 29th, 2026 6:00 am
Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR) - Apr 15th, 2026 4:35 am
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development - Mar 31st, 2026 7:11 am
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts - Mar 24th, 2026 6:00 am
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - Mar 10th, 2026 6:47 am
Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR - Mar 6th, 2026 1:00 pm
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma - Mar 4th, 2026 7:15 am
Citius Oncology (CTOR) Expands LYMPHIR Distribution to Europe Through Exclusive Agreement With Uniphar - Feb 24th, 2026 7:35 am
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ - Feb 13th, 2026 6:00 am
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ - Feb 13th, 2026 6:00 am
Citius Oncology and Uniphar sign European distribution deal for Lymphir - Feb 12th, 2026 4:55 am
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar - Feb 11th, 2026 6:00 am
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - Dec 23rd, 2025 2:30 pm